VIRGINIA RETIREMENT SYSTEMS ET Al Buys 55,650 Shares of Arvinas, Inc. $ARVN

VIRGINIA RETIREMENT SYSTEMS ET Al grew its position in Arvinas, Inc. (NASDAQ:ARVN) by 371.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,650 shares of the company’s stock after acquiring an additional 55,650 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al owned about 0.11% of Arvinas worth $838,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of ARVN. AQR Capital Management LLC bought a new position in shares of Arvinas in the 1st quarter valued at about $727,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Arvinas in the 1st quarter valued at about $301,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Arvinas by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock valued at $271,000 after acquiring an additional 2,122 shares during the period. Millennium Management LLC grew its position in shares of Arvinas by 208.4% in the 1st quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock valued at $9,198,000 after acquiring an additional 885,483 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Arvinas by 108.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 902,925 shares of the company’s stock valued at $6,339,000 after acquiring an additional 469,394 shares during the period. Institutional investors own 95.19% of the company’s stock.

Analyst Upgrades and Downgrades

ARVN has been the subject of a number of analyst reports. BTIG Research lifted their price objective on shares of Arvinas from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Barclays lifted their price objective on shares of Arvinas from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday. Piper Sandler reaffirmed an “overweight” rating and set a $20.00 price objective (up from $16.00) on shares of Arvinas in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arvinas in a research report on Friday, April 10th. Finally, Wedbush lifted their price objective on shares of Arvinas from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 24th. Eight analysts have rated the stock with a Buy rating, three have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Arvinas presently has a consensus rating of “Hold” and an average target price of $14.69.

Arvinas News Roundup

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: BTIG Research raised its price target on Arvinas to $18 from $16 and reiterated a Buy rating, signaling continued Wall Street confidence in upside potential. Arvinas (NASDAQ:ARVN) Price Target Raised to $18.00 at BTIG Research
• Positive Sentiment: Arvinas and Pfizer’s breast cancer drug vepdegestrant was licensed to Rigel Pharmaceuticals in a deal that includes $85 million upfront and up to $320 million in milestones, which supports the value of Arvinas’ PROTAC platform and adds potential non-dilutive funding. Rigel strikes licensing deal for Pfizer and Arvinas’ breast cancer drug
• Neutral Sentiment: HC Wainwright modestly adjusted several earnings forecasts for Arvinas, including lower estimates for 2026-2029 and a small cut to FY2030 EPS, reflecting ongoing uncertainty around future profitability rather than a major new development.
• Neutral Sentiment: Arvinas recently beat Q1 EPS estimates, but revenue missed expectations and dropped sharply year over year, reinforcing that the company remains far from sustained profitability. Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: Recent insider selling by the CEO, CFO, CAO, and another executive may be pressuring sentiment, even though the sales were disclosed as tax-withholding transactions tied to equity vesting. CEO insider filing

Arvinas Stock Performance

NASDAQ:ARVN opened at $9.08 on Monday. The stock has a fifty day moving average price of $10.97 and a 200-day moving average price of $11.69. Arvinas, Inc. has a fifty-two week low of $6.05 and a fifty-two week high of $14.51. The company has a market cap of $585.84 million, a price-to-earnings ratio of -2.73 and a beta of 1.79.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.05. Arvinas had a negative net margin of 247.54% and a negative return on equity of 44.38%. The company had revenue of $15.60 million during the quarter, compared to the consensus estimate of $16.61 million. During the same quarter in the prior year, the firm posted $1.14 EPS. The firm’s quarterly revenue was down 91.7% on a year-over-year basis. Research analysts predict that Arvinas, Inc. will post -2.85 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Briggs Morrison acquired 20,000 shares of the stock in a transaction dated Friday, March 6th. The stock was bought at an average cost of $13.40 per share, for a total transaction of $268,000.00. Following the completion of the transaction, the director directly owned 96,021 shares of the company’s stock, valued at $1,286,681.40. The trade was a 26.31% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Randy Teel sold 9,657 shares of Arvinas stock in a transaction on Monday, May 11th. The stock was sold at an average price of $9.94, for a total transaction of $95,990.58. Following the transaction, the chief executive officer directly owned 287,218 shares of the company’s stock, valued at $2,854,946.92. This represents a 3.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 81,449 shares of company stock worth $945,574 over the last 90 days. Insiders own 7.30% of the company’s stock.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.